Ralimetinib
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc[1].
Product Specifications
CAS Number
862505-00-8
Product Name Alternative
LY2228820
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; p38 MAPK
Type
Reference compound
Related Pathways
Autophagy; MAPK/ERK Pathway
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ralimetinib.html
Purity
98.58
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC1=NC2=CC=C(C3=C(C4=CC=C(F)C=C4)N=C(C(C)(C)C)N3)N=C2N1CC(C)(C)C
Molecular Formula
C24H29FN6
Molecular Weight
420.53
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
P38α; p38β
Citation 01
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![MiTF Recombinant Rabbit Monoclonal Antibody [JF100-01]](https://cdn.genprice.uk/products/992/68dd1c8e061270361ea824f1/imageurl/et1702-86.webp)
MiTF Recombinant Rabbit Monoclonal Antibody [JF100-01]
